Drug Discovery

Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read More

Using computer-aided drug design, Heidi Hamm, Craig Lindsley, and Jens Meiler and their labs generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read More

On October 17, 2022, Vanderbilt University launched “Discovery Vanderbilt” to embolden faculty, students and staff to pursue innovative ideas through disciplined, rigorous inquiry. Led by Provost Cybele Raver, the university committed $80 million in the effort—and invested $50 million in the first year alone. Read More

Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read More

Biomedical engineer David Merryman and Warren Center for Neuroscience Drug Discovery director Craig Lindsley have developed a new drug that treats PAH, a type of high blood pressure that affects arteries in the lungs and in the heart, without serious neurological side effects. Read More

Vanderbilt's Center for Technology Transfer and Commercialization named Richard Caprioli, C. David Weaver, Susan Eagle, and Franz Baudenbacher 2023 Master Innovators. The yearly recognition program acknowledges Vanderbilt’s top innovators and entrepreneurs for their contributions to the creation, development, and commercialization of intellectual property. Read More

The laboratories of Brian Bachmann and Jonathan Irish have developed a method to discover new small molecules that may kill cancer cells by working through the body’s immune system. Read More

Warren Center for Neuroscience Drug Discovery lead researchers discover a therapy that may treat memory loss and slow the progression of Alzheimer’s disease. Read More

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read More

Gregor Neuert has discovered that cells respond differently to acute and gradual stress. This finding will transform how cell signaling is understood and inform the drug discovery processes. Read More

Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research. Read More

Sirenas, a San Diego-based company founded by Vanderbilt alumni Eduardo Esquenazi, BS'98, and Jake Beverage, BA'98, is applying trailblazing methods toward drug discovery. Read More

The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals. Read More

Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature. Read More

Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development. Read More

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers. Read More

The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos. Read More

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia. Read More

An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy. Read More

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development. Read More